drugset / Trial / NCT02510599

Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis

NCT02510599

Phase 2 Completed 10 enrolled Melinta Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects of solithromycin on hepatic histology and biomarkers in patients with nonalcoholic steatohepatitis.

Timeline

Start
2015-12
Primary completion
2017-01-27
Completion
2017-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Solithromycin Other / unclassified 200 mg Oral